The epithelial-mesenchymal transition (EMT) is a fundamental biological "shape-shifting" process where stationary, polarized epithelial cells lose their cell-to-cell adhesion and transform into mobile, invasive mesenchymal cells. In the context of oncology, this transition serves as a critical engine for metastasis, allowing tumor cells to detach from a primary site, navigate the circulatory system, and colonize distant organs.
The Cadherin Switch and Structural Reprogramming
At its core, EMT is a physical transformation driven by a representational shift in the cell's structural proteins. Epithelial cells are defined by high levels of E-cadherin, a protein that acts like molecular Velcro, anchoring cells to their neighbors. During EMT, cells undergo what is often termed a "cadherin switch."
As Gaojie Liu et al. demonstrate in their study of Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients, this process involves the systematic suppression of these adhesion proteins and the simultaneous upregulation of mesenchymal markers like N-cadherin and Vimentin. These new proteins act more like engines than anchors, facilitating cellular movement and tissue invasion. Jing Yuan et al. further clarify this in SHROOM2 inhibits tumor metastasis through RhoA–ROCK pathway-dependent and -independent mechanisms in nasopharyngeal carcinoma, showing that the loss of specific structural proteins triggers a spindle-like mesenchymal phenotype, allowing cells to break away from the primary tumor.
Microenvironmental Triggers and Signaling Hubs
EMT does not happen in a vacuum; it is a response to specific signals within the tumor microenvironment. One of the most potent triggers is hypoxia (low oxygen). Zhuoxin Cheng et al. found in Nuclear Factor-κB–Dependent Epithelial to Mesenchymal Transition Induced by HIF-1α Activation in Pancreatic Cancer Cells under Hypoxic Conditions that oxygen deprivation activates the HIF-1α/NF-κB signaling pathway, which serves as a bridge between environmental stress and the molecular reprogramming of the cell.
External cellular "messengers" also play a role. Simeng Wu et al. show in Human adipose‑derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial‑mesenchymal transition by cross interacting with the TGF‑β/Smad and PI3K/AKT signaling pathways that mesenchymal stem cells can secrete TGF-β1, which activates a crosstalk between the Smad and Akt pathways to induce EMT. Similarly, Hongbing Gu et al. demonstrate in Exosomes derived from human mesenchymal stem cells promote gastric cancer cell growth and migration via the activation of the Akt pathway that tiny communication vesicles (exosomes) can flip the molecular switch for EMT by activating the Akt pathway.
The Link to Stemness and Treatment Resistance
EMT is often coupled with the acquisition of "stemness"—the ability of a cell to self-renew and differentiate. This link explains why metastatic cells are not only mobile but also highly resilient. Deli Mao et al. argue in Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer that cellular stemness serves as a critical driver of EMT, directly influencing a tumor's potential for systemic progression.
This transformation also confers resistance to standard therapies. For example, Xiaohui Yu 0001 et al. demonstrate in Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition that the stabilization of the protein CDC6 allows cells to bypass radiation-induced death and enter an EMT state, making them both treatment-resistant and highly invasive. Similarly, Huan Liu et al. show in Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity that EMT markers are closely tied to chemoresistance, and reversing this transition can make cancer cells susceptible to drugs like gemcitabine again.
Therapeutic Reversal: Inducing MET
Because EMT is a plastic process, researchers are exploring ways to reverse it—a process known as the Mesenchymal-Epithelial Transition (MET). By targeting the transcription factors that drive EMT, such as Snail or SOX2, it is possible to "lock" cells back into a stationary state.
Yicheng Xiong et al. show in MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells that microRNAs can be used to suppress Snail, preventing cells from invading. Furthermore, natural compounds have shown promise; Pan Zhao demonstrates in Curcumin inhibits epithelial-mesenchymal transition in colorectal cancer cells by regulating miR-206/SNAI2 pathway that curcumin can inhibit EMT by regulating the miR-206/SNAI2 pathway, effectively reducing the metastatic potential of colorectal cancer cells.